{"pmid":32500939,"title":"Controversies Regarding Shielding and Susceptibility to COVID-19 Disease in Liver transplant Recipients in the United Kingdom.","text":["Controversies Regarding Shielding and Susceptibility to COVID-19 Disease in Liver transplant Recipients in the United Kingdom.","December 2019 saw the emergence of a novel coronavirus, SARS-CoV-2, which rapidly escalated to a global pandemic (1) , with an unprecedented impact on healthcare systems worldwide. The objective of this case series is to report on SARS-CoV-2 infection in liver transplant recipients and discuss the role of immunosuppression, comorbidities and shielding. In the UK, transplant recipients were classified as individuals vulnerable to SARS-CoV-2 infection due to immunosuppression. They were advised in late March 2020 (Figure 1) by Public Health England to take additional social distancing precautions, a process referred to as 'shielding' (2) . This is a more rigorous form of isolation that requires the individual to not leave their place of residence or come into contact with others. In essence, completely isolate to minimise the risk of being exposed to SARS-CoV-2.","Transpl Infect Dis","Hann, A","Lembach, H","McKay, S C","Perrin, M","Isaac, J","Oo, Y H","Mutimer, D","Mirza, D F","Hartog, H","Perera, Mtpr","32500939"],"abstract":["December 2019 saw the emergence of a novel coronavirus, SARS-CoV-2, which rapidly escalated to a global pandemic (1) , with an unprecedented impact on healthcare systems worldwide. The objective of this case series is to report on SARS-CoV-2 infection in liver transplant recipients and discuss the role of immunosuppression, comorbidities and shielding. In the UK, transplant recipients were classified as individuals vulnerable to SARS-CoV-2 infection due to immunosuppression. They were advised in late March 2020 (Figure 1) by Public Health England to take additional social distancing precautions, a process referred to as 'shielding' (2) . This is a more rigorous form of isolation that requires the individual to not leave their place of residence or come into contact with others. In essence, completely isolate to minimise the risk of being exposed to SARS-CoV-2."],"journal":"Transpl Infect Dis","authors":["Hann, A","Lembach, H","McKay, S C","Perrin, M","Isaac, J","Oo, Y H","Mutimer, D","Mirza, D F","Hartog, H","Perera, Mtpr"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32500939","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/tid.13352","locations":["GBR","Liver","United Kingdom"],"countries":["United Kingdom"],"countries_codes":["GBR|United Kingdom"],"topics":["Prevention"],"weight":1,"_version_":1668890966301343744,"score":9.490897,"similar":[{"pmid":32471013,"title":"Low prevalence and disease severity of COVID-19 in post liver transplant recipients - a single centre experience.","text":["Low prevalence and disease severity of COVID-19 in post liver transplant recipients - a single centre experience.","Coronavirus disease 2019 (COVID-19) caused by a novel coronavirus called severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is driving a present day global pandemic. Immunosuppressed patients are regarded as a high risk cohort. The following is a short report on COVID-19 in liver transplant recipients (n=5) from a high volume UK liver transplant unit with a large follow up cohort (n=4500). Based on this limited data, liver transplant recipients appear to have a low incidence of COVID-19, with less severe symptoms than expected, when compared to the general population and other solid organ recipients. This possibly could be related to self-isolation adherence and/or the \"ideal\" level of immunosuppression that favourably modulates the immune response to COVID-19.","Liver Int","Verma, Anita","Khorsandi, Shirin Elizabeth","Dolcet, Annalisa","Prachalias, Andreas","Suddle, Abid","Heaton, Nigel","Jassem, Wayel","32471013"],"abstract":["Coronavirus disease 2019 (COVID-19) caused by a novel coronavirus called severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is driving a present day global pandemic. Immunosuppressed patients are regarded as a high risk cohort. The following is a short report on COVID-19 in liver transplant recipients (n=5) from a high volume UK liver transplant unit with a large follow up cohort (n=4500). Based on this limited data, liver transplant recipients appear to have a low incidence of COVID-19, with less severe symptoms than expected, when compared to the general population and other solid organ recipients. This possibly could be related to self-isolation adherence and/or the \"ideal\" level of immunosuppression that favourably modulates the immune response to COVID-19."],"journal":"Liver Int","authors":["Verma, Anita","Khorsandi, Shirin Elizabeth","Dolcet, Annalisa","Prachalias, Andreas","Suddle, Abid","Heaton, Nigel","Jassem, Wayel"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32471013","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/liv.14552","locations":["GBR"],"countries":["United Kingdom"],"countries_codes":["GBR|United Kingdom"],"topics":["Prevention"],"weight":1,"_version_":1668420887282450432,"score":250.67535},{"pmid":32500942,"title":"Outcome of COVID-19 in Liver Transplant Recipients: a Preliminary Report from Northwestern Italy.","text":["Outcome of COVID-19 in Liver Transplant Recipients: a Preliminary Report from Northwestern Italy.","Covid-19 pandemic is deeply affecting transplant activity worldwide. It is unclear whether solid organ transplant recipients are at increased risk of developing severe complications and how they should be managed, also concerning immunosuppression. This is a report about the course and management of SARS-CoV-2 infection in liver transplant recipients from a single center in Northwestern Italy in the period March-April 2020. Three patients who were treated at our Institution are reported in details, whereas summary data are provided for those managed at peripheral Hospitals. Presentation varied from asymptomatic to rapidly progressive respiratory failure due to bilateral interstitial pneumonia. Accordingly, treatment and changes to immunosuppression were adapted to the severity of the disease. Overall mortality was 20%, whereas Covid-related mortality was 10%. Two cases of prolonged (> 2 months) viral carriage were observed in two asymptomatic patients who contracted the infection in the early course after transplant. Besides depicting Covid-19 course and possible treatment scenarios in liver transplant patients, these cases are discussed in relation to the changes in our practice prompted by Covid-19 epidemic, with potential implications for other transplant programs.","Transpl Infect Dis","Patrono, Damiano","Lupo, Francesco","Canta, Francesca","Mazza, Elena","Mirabella, Stefano","Corcione, Silvia","Tandoi, Francesco","De Rosa, Francesco Giuseppe","Romagnoli, Renato","32500942"],"abstract":["Covid-19 pandemic is deeply affecting transplant activity worldwide. It is unclear whether solid organ transplant recipients are at increased risk of developing severe complications and how they should be managed, also concerning immunosuppression. This is a report about the course and management of SARS-CoV-2 infection in liver transplant recipients from a single center in Northwestern Italy in the period March-April 2020. Three patients who were treated at our Institution are reported in details, whereas summary data are provided for those managed at peripheral Hospitals. Presentation varied from asymptomatic to rapidly progressive respiratory failure due to bilateral interstitial pneumonia. Accordingly, treatment and changes to immunosuppression were adapted to the severity of the disease. Overall mortality was 20%, whereas Covid-related mortality was 10%. Two cases of prolonged (> 2 months) viral carriage were observed in two asymptomatic patients who contracted the infection in the early course after transplant. Besides depicting Covid-19 course and possible treatment scenarios in liver transplant patients, these cases are discussed in relation to the changes in our practice prompted by Covid-19 epidemic, with potential implications for other transplant programs."],"journal":"Transpl Infect Dis","authors":["Patrono, Damiano","Lupo, Francesco","Canta, Francesca","Mazza, Elena","Mirabella, Stefano","Corcione, Silvia","Tandoi, Francesco","De Rosa, Francesco Giuseppe","Romagnoli, Renato"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32500942","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/tid.13353","keywords":["covid-19","early infection","immunosuppression","viral carriage"],"topics":["Case Report"],"weight":1,"_version_":1668890966355869697,"score":231.47614},{"pmid":32476258,"title":"Clinical Outcomes and Serologic Response in Solid Organ Transplant Recipients with COVID-19: A Case Series from the United States.","text":["Clinical Outcomes and Serologic Response in Solid Organ Transplant Recipients with COVID-19: A Case Series from the United States.","The coronavirus disease 2019 (COVID-19) pandemic caused by SARS coronavirus 2 (SARS-CoV-2) has caused significant morbidity and mortality for patients and stressed healthcare systems worldwide. The clinical features, disease course, and serologic response of COVID-19 among immunosuppressed patients such as solid organ transplant (SOT) recipients, who are at presumed risk for more severe disease, are not well characterized. We describe our institutional experience with COVID-19 among ten SOT patients, including the clinical presentation, treatment modalities, and outcomes of seven renal transplant recipients, one liver transplant recipient, one heart transplant recipient, and one lung transplant recipient. In addition, we report the serologic response in SOT recipients, documenting a positive IgG response in all seven hospitalized patients. We also review the existing literature on COVID-19 in SOT recipients to consolidate the current knowledge on COVID-19 in the SOT population for the transplant community.","Am J Transplant","Fung, Monica","Chiu, Charles Y","DeVoe, Catherine","Doernberg, Sarah B","Schwartz, Brian S","Langelier, Charles","Henrich, Timothy J","Yokoe, Deborah","Davis, John","Hays, Steven R","Chandran, Sindhu","Kukreja, Jasleen","Ng, Dianna","Prostko, John","Taylor, Russell","Reyes, Kevin","Bainbridge, Emma","Bond, Allison","Chin-Hong, Peter","Babik, Jennifer M","32476258"],"abstract":["The coronavirus disease 2019 (COVID-19) pandemic caused by SARS coronavirus 2 (SARS-CoV-2) has caused significant morbidity and mortality for patients and stressed healthcare systems worldwide. The clinical features, disease course, and serologic response of COVID-19 among immunosuppressed patients such as solid organ transplant (SOT) recipients, who are at presumed risk for more severe disease, are not well characterized. We describe our institutional experience with COVID-19 among ten SOT patients, including the clinical presentation, treatment modalities, and outcomes of seven renal transplant recipients, one liver transplant recipient, one heart transplant recipient, and one lung transplant recipient. In addition, we report the serologic response in SOT recipients, documenting a positive IgG response in all seven hospitalized patients. We also review the existing literature on COVID-19 in SOT recipients to consolidate the current knowledge on COVID-19 in the SOT population for the transplant community."],"journal":"Am J Transplant","authors":["Fung, Monica","Chiu, Charles Y","DeVoe, Catherine","Doernberg, Sarah B","Schwartz, Brian S","Langelier, Charles","Henrich, Timothy J","Yokoe, Deborah","Davis, John","Hays, Steven R","Chandran, Sindhu","Kukreja, Jasleen","Ng, Dianna","Prostko, John","Taylor, Russell","Reyes, Kevin","Bainbridge, Emma","Bond, Allison","Chin-Hong, Peter","Babik, Jennifer M"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32476258","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/ajt.16079","locations":["United States"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Case Report"],"weight":1,"_version_":1668437834963353600,"score":219.01193},{"pmid":32439237,"title":"Liver transplantation in the era of COVID-19.","text":["Liver transplantation in the era of COVID-19.","Liver transplantation is considered the ultimate solution for patients with end-stage chronic liver disease or acute liver failure. Patients with liver transplant need special care starting from preoperative preparation, surgical intervention ending with postoperative care. Transplanted patients have to receive immunosuppressive therapy to prevent rejection. Such a state of immune suppression could predispose to different types of infections in liver transplant recipients. Currently, the world is suffering a pandemic caused by a new strain of the coronavirus family called COVID-19. Certain infection control precautions are needed to protect immunocompromised and vulnerable patients, including liver transplant candidates and recipients from acquiring COVID-19 infection. Restricting non-transplant elective surgical procedures, managing transplant patients in separate outpatient clinics, and in-patient wards can prevent transmission of infection both to patients and healthcare workers. Telemedicine can help in the triage of patients to screen for symptoms of COVID-19 before their regular appointment. Management of immunosuppressive therapy and drug-drug interactions in liver transplant recipients infected with COVID-19 should be cautiously practiced to prevent rejection and effectively treat the underlying infection. In this report, we are trying to summarize available evidence about different aspects of the management of liver transplant candidates and recipients in the era of COVID-19.","Arab J Gastroenterol","El Kassas, Mohamed","Alboraie, Mohamed","Al Balakosy, Amira","Abdeen, Nermeen","Afify, Shimaa","Abdalgaber, Mohammad","Sherief, Ahmed F","Madkour, Ahmad","Abdellah Ahmed, Mohamed","Eltabbakh, Mohamed","Salaheldin, Mohamed","Wifi, Mohamed-Naguib","32439237"],"abstract":["Liver transplantation is considered the ultimate solution for patients with end-stage chronic liver disease or acute liver failure. Patients with liver transplant need special care starting from preoperative preparation, surgical intervention ending with postoperative care. Transplanted patients have to receive immunosuppressive therapy to prevent rejection. Such a state of immune suppression could predispose to different types of infections in liver transplant recipients. Currently, the world is suffering a pandemic caused by a new strain of the coronavirus family called COVID-19. Certain infection control precautions are needed to protect immunocompromised and vulnerable patients, including liver transplant candidates and recipients from acquiring COVID-19 infection. Restricting non-transplant elective surgical procedures, managing transplant patients in separate outpatient clinics, and in-patient wards can prevent transmission of infection both to patients and healthcare workers. Telemedicine can help in the triage of patients to screen for symptoms of COVID-19 before their regular appointment. Management of immunosuppressive therapy and drug-drug interactions in liver transplant recipients infected with COVID-19 should be cautiously practiced to prevent rejection and effectively treat the underlying infection. In this report, we are trying to summarize available evidence about different aspects of the management of liver transplant candidates and recipients in the era of COVID-19."],"journal":"Arab J Gastroenterol","authors":["El Kassas, Mohamed","Alboraie, Mohamed","Al Balakosy, Amira","Abdeen, Nermeen","Afify, Shimaa","Abdalgaber, Mohammad","Sherief, Ahmed F","Madkour, Ahmad","Abdellah Ahmed, Mohamed","Eltabbakh, Mohamed","Salaheldin, Mohamed","Wifi, Mohamed-Naguib"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32439237","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.ajg.2020.04.019","keywords":["covid-19","coronavirus","liver transplantation"],"topics":["Prevention"],"weight":1,"_version_":1667523504770121729,"score":217.81592},{"pmid":32277387,"pmcid":"PMC7146012","title":"Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation.","text":["Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation.","Annually, around 850 liver transplantation is performed in Beijing, China. Recently, the new coronavirus pneumonia (COVID-19) caused by 2019 novel coronavirus (2019-nCoV) has affected nearly 200 countries worldwide. 2019-nCov can cause severe lung disease, multiple-organ damage, and significant mortalities. Liver transplant recipients, because of long-term oral immunosuppressant effects, may be more susceptible to 2019-nCoV infection and have a worse prognosis than the general population. It is urgent to set up guidelines for the prevention, diagnosis, and treatment of COVID-19 in liver transplant recipients. In this article, we reviewed the clinical aspects of 2019-nCoV infection, characteristics of liver transplant recipients, immunosuppressant usage, and potential drug interactions to provide recommendations to clinical staff managing liver transplant recipients during the COVID-19 epidemic.","Hepatol Int","Liu, Hongling","He, Xi","Wang, Yudong","Zhou, Shuangnan","Zhang, Dali","Zhu, Jiye","He, Qiang","Zhu, Zhijun","Li, Guangming","Sun, Libo","Wang, Jianli","Cheng, Gregory","Liu, Zhenwen","Lau, George","32277387"],"abstract":["Annually, around 850 liver transplantation is performed in Beijing, China. Recently, the new coronavirus pneumonia (COVID-19) caused by 2019 novel coronavirus (2019-nCoV) has affected nearly 200 countries worldwide. 2019-nCov can cause severe lung disease, multiple-organ damage, and significant mortalities. Liver transplant recipients, because of long-term oral immunosuppressant effects, may be more susceptible to 2019-nCoV infection and have a worse prognosis than the general population. It is urgent to set up guidelines for the prevention, diagnosis, and treatment of COVID-19 in liver transplant recipients. In this article, we reviewed the clinical aspects of 2019-nCoV infection, characteristics of liver transplant recipients, immunosuppressant usage, and potential drug interactions to provide recommendations to clinical staff managing liver transplant recipients during the COVID-19 epidemic."],"journal":"Hepatol Int","authors":["Liu, Hongling","He, Xi","Wang, Yudong","Zhou, Shuangnan","Zhang, Dali","Zhu, Jiye","He, Qiang","Zhu, Zhijun","Li, Guangming","Sun, Libo","Wang, Jianli","Cheng, Gregory","Liu, Zhenwen","Lau, George"],"date":"2020-04-12T11:00:00Z","year":2020,"_id":"32277387","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1007/s12072-020-10043-z","keywords":["2019-ncov","covid-19","liver transplantation","management"],"locations":["Beijing","China","Beijing"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Prevention","Diagnosis","Treatment"],"weight":1,"_version_":1666138491597094912,"score":210.19951}]}